We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be attending the American Intellectual Property Law Association (AIPLA) 2026 Spring Meeting. She will also be participating as a speaker at the AIPLA Chemical Patent Practice Institute, presenting on the China perspective at an international panel on written description. The Chemical Patent Practice Institute will take place from May 11 to 12, while the Spring Meeting will take place from May 13 to 15, 2026, at the historic Fairmont San Francisco.

As one of the most significant gatherings for intellectual property professionals in North America, the AIPLA Spring Meeting is a hub for high-level discussion on the legislative and judicial trends shaping the future of IP. This year's program highlights the intersection of innovation and technology, with a deep focus on "The Future of IP in an AI-Driven World."

If you or your firm will be in San Francisco for AIPLA2026, Jennifer would be delighted to meet to discuss cross-border patent strategies or our specialized services in China. Please reach out to us to schedule a meeting during the conference.

Our Past Events

Recommended Insights

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

11 December 2020
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

10 November 2023
On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see […]

Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments

22 July 2026
Managing global pharmaceutical or chemical portfolios requires navigating China’s notoriously rigid standards on the "same subject matter" requirement for priority and claim amendments. A recent invalidation decision (No. 588094) issued by the China National Intellectual Property Administration (CNIPA) concerning a pharmaceutical patent provides clarity on how numerical ranges and later added experimental data are evaluated […]

Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?

19 August 2021
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Seminal Cases by the SPC Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for […]
Top crossarrow-right